NO20055747L - Stabile, vandige losninger av human erytropoietin som ikke inneholder serumalbumin - Google Patents

Stabile, vandige losninger av human erytropoietin som ikke inneholder serumalbumin

Info

Publication number
NO20055747L
NO20055747L NO20055747A NO20055747A NO20055747L NO 20055747 L NO20055747 L NO 20055747L NO 20055747 A NO20055747 A NO 20055747A NO 20055747 A NO20055747 A NO 20055747A NO 20055747 L NO20055747 L NO 20055747L
Authority
NO
Norway
Prior art keywords
human erythropoietin
serum albumin
aqueous solutions
stable aqueous
contain serum
Prior art date
Application number
NO20055747A
Other languages
English (en)
Norwegian (no)
Other versions
NO20055747D0 (no
Inventor
Kyu Chan Kwon
Suk Young Choi
Hoon Sung Jeh
Seung Joo Lee
Myung Jin Kim
Ji Eon Kim
Jin-Seok Oh
Yong Cheol Kang
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36337525&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20055747(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of NO20055747D0 publication Critical patent/NO20055747D0/no
Publication of NO20055747L publication Critical patent/NO20055747L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1816Erythropoietin [EPO]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
NO20055747A 2003-06-10 2005-12-05 Stabile, vandige losninger av human erytropoietin som ikke inneholder serumalbumin NO20055747L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20030037060 2003-06-10
PCT/KR2004/001358 WO2004108152A1 (en) 2003-06-10 2004-06-07 Stable, aqueous solution of human erythropoietin, not containing serum albumin

Publications (2)

Publication Number Publication Date
NO20055747D0 NO20055747D0 (no) 2005-12-05
NO20055747L true NO20055747L (no) 2006-03-07

Family

ID=36337525

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055747A NO20055747L (no) 2003-06-10 2005-12-05 Stabile, vandige losninger av human erytropoietin som ikke inneholder serumalbumin

Country Status (19)

Country Link
US (1) US8119595B2 (xx)
EP (1) EP1641486B1 (xx)
JP (1) JP4871720B2 (xx)
KR (1) KR100610003B1 (xx)
CN (1) CN1802171B (xx)
AT (1) ATE553747T1 (xx)
AU (1) AU2004244920B2 (xx)
BR (1) BRPI0411114B8 (xx)
CA (1) CA2528988C (xx)
EA (1) EA009676B1 (xx)
ES (1) ES2385888T3 (xx)
HK (1) HK1093012A1 (xx)
MX (1) MXPA05013398A (xx)
NO (1) NO20055747L (xx)
NZ (1) NZ543859A (xx)
PL (1) PL379272A1 (xx)
UA (1) UA82241C2 (xx)
WO (1) WO2004108152A1 (xx)
ZA (1) ZA200509222B (xx)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY139088A (en) 2005-02-21 2009-08-28 Lg Life Sciences Ltd Sustained release composition of protein drug
WO2007108505A1 (ja) 2006-03-22 2007-09-27 Chugai Seiyaku Kabushiki Kaisha エリスロポエチン溶液製剤
DE102007050165B4 (de) * 2007-10-19 2010-06-17 Stiftung Tierärztliche Hochschule Hannover Stabilisierte Lösung, Verfahren zu deren Herstellung sowie deren Verwendung und Arzneimittel in Form einer stabilisierten Lösung
WO2009064838A1 (en) 2007-11-15 2009-05-22 Amgen, Inc. Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
JP5770629B2 (ja) * 2008-08-15 2015-08-26 アイアンウッド ファーマシューティカルズ インコーポレイテッド 経口投与に好適なgc−c受容体アゴニストポリペプチドの安定な固体製剤
CA2770077A1 (en) * 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
US8829163B2 (en) * 2010-01-19 2014-09-09 Hanmi Science Co., Ltd Liquid formulations for long-acting erythropoietin conjugate
CN102869677B (zh) 2010-02-17 2015-07-08 硬木药品公司 胃肠病症的治疗
SI2603232T1 (sl) 2010-08-11 2020-03-31 Ironwood Pharmaceuticals, Inc. Stabilne formulacije linaklotida
KR101303388B1 (ko) * 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
MX347354B (es) 2011-08-17 2017-04-24 Ironwood Pharmaceuticals Inc Tratamientos para trastornos gastrointestinales.
BR112015022587A2 (pt) * 2013-03-13 2017-10-24 Eleven Biotherapeutics Inc formulações de citocina quimérica para entrega ocular
EP2832361A1 (en) * 2013-07-29 2015-02-04 Ipsen Pharma S.A.S. Aqueous sustained release compositions of LHRH analogs
DK3287141T3 (da) * 2015-04-21 2021-10-11 Staidson Beijing Biopharmaceuticals Co Ltd Nervevækstfaktorsammensætning og injektionspulver
WO2023098844A1 (zh) * 2021-12-03 2023-06-08 杰科(天津)生物医药有限公司 一种制剂及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
JPS6191131A (ja) 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd 医薬品の吸着防止方法および組成物
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
DE3729863A1 (de) 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
GB9001987D0 (en) * 1990-01-29 1990-03-28 Janssen Pharmaceutica Nv Improved cyclodextrin based erythropietin formulation
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US5661125A (en) 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
TWI240627B (en) * 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
EP1015008B1 (en) * 1997-02-07 2015-08-05 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
TW570805B (en) * 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
WO2000015241A1 (fr) * 1998-09-11 2000-03-23 Chugai Seiyaku Kabushiki Kaisha Preparation d'une solution proteinique et son procede de stabilisation
BR0010665A (pt) * 1999-04-09 2004-03-09 Ortho Mcneil Pharm Inc ComposiçÈes farmacêuticas de eritropoietina
EP1232753B1 (en) * 1999-09-08 2008-03-19 Chugai Seiyaku Kabushiki Kaisha Stable protein solution filled in a container made from a hydrophobic resin and method of stabilizing the same
EP1260230A4 (en) * 2000-02-29 2008-08-06 Chugai Pharmaceutical Co Ltd LONG-TERM STABILIZED PREPARATIONS
JP3967594B2 (ja) * 2000-05-15 2007-08-29 エフ.ホフマン−ラ ロシュ アーゲー 新しい薬剤組成物
SI21258A (sl) * 2002-07-17 2004-02-29 LEK farmacevtska dru�ba d.d. Stabilni farmacevtski pripravek, ki vsebuje eritropoietin in poloksamerni poliol

Also Published As

Publication number Publication date
CN1802171A (zh) 2006-07-12
UA82241C2 (uk) 2008-03-25
BRPI0411114B8 (pt) 2021-05-25
AU2004244920A1 (en) 2004-12-16
EA009676B1 (ru) 2008-02-28
CA2528988A1 (en) 2004-12-16
NO20055747D0 (no) 2005-12-05
MXPA05013398A (es) 2006-03-09
ES2385888T3 (es) 2012-08-02
EP1641486B1 (en) 2012-04-18
HK1093012A1 (en) 2007-02-23
JP4871720B2 (ja) 2012-02-08
US8119595B2 (en) 2012-02-21
NZ543859A (en) 2008-01-31
EP1641486A1 (en) 2006-04-05
EA200501789A1 (ru) 2006-06-30
PL379272A1 (pl) 2006-08-21
AU2004244920B2 (en) 2009-07-23
BRPI0411114B1 (pt) 2020-09-15
US20070293419A1 (en) 2007-12-20
EP1641486A4 (en) 2008-10-08
KR100610003B1 (ko) 2006-08-08
ZA200509222B (en) 2006-09-27
KR20040110994A (ko) 2004-12-31
BRPI0411114A (pt) 2006-07-18
CN1802171B (zh) 2010-10-13
JP2007528842A (ja) 2007-10-18
WO2004108152A1 (en) 2004-12-16
ATE553747T1 (de) 2012-05-15
CA2528988C (en) 2012-05-01

Similar Documents

Publication Publication Date Title
NO20055747D0 (no) Stabile, vandige losninger av human erytropoietin som ikke inneholder serumalbumin
DE60334678D1 (de) Antikörper enthaltende pharmazeutische lösungen
HRP20110094T8 (en) Solid preparation comprising alogliptin and pioglitazone
WO2009013435A3 (fr) Solution ophtalmique à base de prostaglandines sans conservateur
CO5660273A2 (es) Formulaciones de proteina y anticuerpo de alta concentracion
WO2007069214A3 (en) Wet wipes with natural antimicrobial agents
WO2013016648A3 (en) Stabilized formulations containing anti-pcsk9 antibodies
CR10032A (es) Preparación sólida
HRP20060147B1 (hr) Terapijski sustav s kontroliranim otpuštanjem za nazalnu primjenu
CR10290A (es) Metodos para reducir la aglomeracion de proteina
WO2007019232A3 (en) Immunoconjugate formulations
DK1605932T3 (da) Intranasal formulering af rotigotin
CL2004000208A1 (es) COMPOSICION FARMACEUTICA QUE COMPRENDE: i) UNA BASE LIQUIDA CON 50-300mg/100ml DE SUCRALOSA PARA DISIMULAR SABOR AMARGO DE UN ACTIVO Y II) AL MENOS UN ACTIVO SELECCIONADO ENTRE ANTIHISTAMINAS, DESCONGESTIONANTES, ANTITUSIVOS, EXPECTORANTES, ANTIBIOTI
CR7614A (es) Preparaciones de insulina acida con estabilidad mejorada
MX2007012443A (es) Formulaciones farmaceuticas orales que comprenden acido fenofibrico y/o sus sales.
WO2006110482A3 (en) Borate-polyol mixtures as a buffering system
DK1372608T3 (da) Medicinske aerosolformuleringer
WO2004091656A3 (fr) Formulation stabilisante pour compositions d'immunoglobulines G sous forme liquide et sous forme lyophilisEe
BRPI0418115A (pt) formulação lìquida estável de hormÈnio de crescimento
FR2881349B1 (fr) Nouvelle utilisation des galactomannanes en tant qu'agent actif en cosmetique.
NO20065791L (no) Asyklovir-formuleringer
WO2009069288A1 (ja) 毛髪化粧料
EA200701776A1 (ru) Композиция для ухода за контактными линзами
WO2002068575A8 (en) Liquid detergent composition exhibiting enhanced α-amylase enzyme stability
FR2886846B1 (fr) Nouvelles utilisations de derives du glycerol, notamment dans le domaine cosmetique

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application